Selection for the Vickers Award is a considerable honour and carries an implication of personal achievement of some magnitude. It may take the form of a brilliant discovery or, if one is fortunate enough to be in the right position, achievement is simply part of everyday work. Here at the Clinical Research Centre (CRC) we are very conscious of being favourably placed to do interesting things, and indeed our remit is to make some sort of national and international impact in our various specialties. This happy and, as we find it, almost unique position in the world of clinical chemistry becomes a little difficult when, as has happened in the past, awards are bestowed on any member of staff. There was a time when brilliant work in our profession was done by individuals, but this is now rare and team work is required if progress is to be made in almost any area of our specialty; sometimes, because of cost and complexity, centres in several different countries need to be involved. Then again, with advancing years so many of us find we are increasingly concerned with the philosophies involved in the work, selecting areas of activity and creating the environment for that activity to be successful. I should like to cover to some extent the philosophy behind our approach at the CRC to the many problems we have in clinical chemistry, and then to give a few practical examples of how that philosophy is applied.
It is a pleasure to take this opportunity to thank the many colleagues who have contributed in many ways, a few of which will be highlighted later. We in the Association of Clinical Biochemists are grateful to Vickers for funding this award for so many years. The Company and I have been associated for nearly four decades, from the war years when I flew their planes, to a more peaceful involvement in the late 1960s and early 1970s in the development of the M-300 and D-300 analysers. The results from both of these instruments must have formed the basis of a large number of papers from almost every research division at the CRe.
The future of clinical chemistry
The philosophies mentioned earlier concern the future of our specialty-something that should worry us all, but especially our younger members; it is pertinent to quote from Chairman Mao when he addressed the youth of China-'The world is yours as well as ours, but in the last analysis it is yours'. For clinical chemistry the next decade could well be of crucial importance. Chairman Mao brought China out of a mediaeval economy but the future of that country now depends upon those he was addressing 25 years ago.
In comparison with most of the established components of clinical medicine, clinical chemistry is a new specialty. From slow beginnings between the wars it has made dramatic progress, but there are many examples elsewhere where rapid expansion has been followed by equally rapid moves in other, perhaps unexpected directions.
In the Clinical Chemistry Division here, the future is of concern perhaps more than elsewhere because research is our raison d'etre and research of necessity deals with futurity. It seems to fall under two headings: (A) that aimed at improving analytical performance, and (8) biochemical research on essentially clinical problems. In Germany, there is a clear differentiation, the first being termed clinical chemistry, the second, clinical biochemistry. Research and development in both could disappear from our grip very easily; (A) is increasingly being taken up by industry and (B) could revert to being the province of other university departments of clinical medicine of all types. For example, the purely clinical divisions at the CRC are fully capable of carrying out high-grade research under almost all the headings that many would ascribe to clinical chemistry. No legislation or dictatorial approach can prevent either of these possibilities taking place, and there is no doubt that the only way we can keep research in our specialty alive is to be so successful that we show ourselves to be indispensable.
The improvement of analytical performance
It is pertinent to identify the trends that could accelerate rapidly on each of the research fronts. 
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Under (A), industry has found our specialty to present a lucrative market and has invested in the development of both chemical systems and instrumentation on a scale such that the annual market in the United States now approaches two billion dollars. The Kodak approach, to be mentioned in more detail later, poses a special and potentially far-reaching problem in that the expertise involved in the production of photographic colour film has to be married to clinical chemistry, and photographic chemists have shown that they can learn what they they require of clinical chemistry much more readily than vice versa. In no way can the necessary research be carried out other than with a background of considerable knowledge of the principles and processes used in modern photography. For industry, clinical chemistry is now big business, and since the focus of much further analytical development has moved from the clinical to the industrial laboratory, many academic and professional clinical chemists must be prepared to move also. In the other direction, several forward-looking companies have taken opportunities to collaborate in the academic and professional area. It must be stressed that movements in both directions are not limited to universities and large research institutes, but many very useful collaborations have evolved with hospital service laboratories world-wide.
University departments and our research staff here must always work in close association with a service department, otherwise research loses its relevance; this is equally true for industry. The strengths we have to offer industry from the profession come from our close connection with the problems, and. with goodwill on both sides, a company's development staff can so easily and so much more effectively make their own development plans, working with us in our own environment. Clinical chemists can be recruited to industry, but then only a short time has to elapse before they are no longer clinically orientated. On the industrial side more collaboration in the past would undoubtedly have prevented some expensive mistakes, and, for the professionals, many impractical ideas which have been nurtured too long could have been relegated earlier to their rightful places in the light of the practicalities of production or commercial sense.
Over the last few decades many members of the specialty have been attracted by the exciting work that has been required in the development of new methodologies, automation, data processing, quality control, and, recently, in the new area of the operational simplification of our systems and instruments; this last has been neglected in the past but now demonstrates a reversal of the previous trend which F. L. Mitchell for 20 years has been based upon the thesis 'biggest is best'. Major breakthroughs under all the above headings have been a feature of our immediate past, but there is no question that the end of the golden age of innovation is in sight. Perhaps there is a decade ahead when exploitation of current potential will be possible, and indeed still exciting; new breakthroughs are, of course, inevitable, but the era of dramatic technological development cannot continue indefinitely. The prospects for the immediate future under each of the headings mentioned above are worthy of study in a little more detail.
METHODOLOGY
For immunoassay, mass spectrometry, electrochemistry, high-performance liquid chromatography (HPLC), and the solid-phase layer chemistry approach, concerted effort is required by both industry and the profession for full exploitation in the laboratory, hospital, and community.
AUTOMATION
For the immediate future there must be preoccupation with the exploitation of the latest generation of fast kinetic analysers and the development of new principles required for working with dry-to-the-touch thin-layer chemistry. The microprocessor is becoming a commonplace component of even relatively simple instruments such as small centrifuges. Developmental initiative in most aspects of automation has, over the last few years, moved increasingly towards industry, but the application of the new developments to the actual improvement of health care lies firmly with the profession.
DATA PROCESSING
Much work has been done on the establishment of the principles of operation required for data processing and development, and consolidation of these will undoubtedly dominate the future.
QUALITY CONTROL
After a long period of concentration upon the control of precision, the accent is now firmly established on the control of accuracy where much work requires to be done in the areas of definitive and reference technology. Industry is not likely to play a major role in this field, but it is proving increasingly necessary to enlist the powerful help and support of colleagues in physical chemistry, with their measurement instruments such as the various types of mass spectrometer. Bastions of the pure chemical sciences, such as the National Bureau of Standards, Washington DC, the European Community Bureau of Reference, Brussels, and the National Physical Laboratory, Teddington, have needed little persuasion to offer their very valuable help on a considerable scale. Their involvement can only increase, as will the participation of the Center for Disease Control, Atlanta, the World Health Organization, and other similar bodies concerned with the development, production, and distribution of materials for accuracy control.
OPERA nON AL SIMPLI FICATION
After 20 years of a tendency to centralise work around large machines in large laboratories there is now a firm tendency to decentralise (Mitchell, 1979) . In many ways the development of mechanisation in clinical chemistry is analogous to the mechanisation of laundering. With the advent of large washing and calender ironing machines the large factory laundry flourished and the problem of the manager was no longer the difficulty of washing the clothes, but collecting and returning them to their rightful owners. So in the large clinical chemistry laboratory the worries of carrying out the chemistry have been considerably reduced in comparison with the looming logistical problems of specimen movement and data processing. The beginning of the demise of the central laundry occurred with the advent of the family washing machine and the do-it-yourself launderette. So, in clinical chemistry, work will necessarily devolve from the central laboratory with the introduction of highly efficient, reasonably priced instruments easily operated by ward staff, GPs, etc. This method of operation is particularly appropriate in developing countries where the large centralised laboratory never could and never will provide the service required.
Research on clinical problems
Under my research category (B) there are many excellent biochemists working in university departments of clinical medicine and indeed in the clinical divisions of the CRe. They do excellent research and are responsible for a high proportion of publications in the field. In looking to the future it is necessary for clinical chemists to ask themselves-if we were to stop working on clinical research and to concentrate only on service assays supporting the clinical research of others, would we be missed? It has been proposed by at least one professor of clinical chemistry that all biochemists employed in university clinical departments should be seconded from the university department of clinical chemistry. There are several good reasons (career prospects, etc) for proposing this, but there are many more cogent reasons 291 why it cannot be, and, even if it were wholly desirable, if it does not take place naturally in no way can it be enforced by legislation. The answer, as always, lies not in trying to lay down rules, but for us as a relatively new profession to continue, perhaps not now so much with expansion but with the accent on entrenchment; to establish that we are indeed a vital part of medical research, and to be so good at it that our clinical colleagues find us to be indispensable both inside and outside their departments.
It is important to remember that research is not confined to academic departments and research institutes; it includes investigative procedures in depth on any particular patient. Any patient not presenting immediately as a clearcut case is a research pro blem of some kind.
To establish the required firm, respected, and lasting relationship with clinicians, the chemical pathologist and the clinical chemist must halt their retreat into the laboratory where they simply provide pieces of paper in response to the receipt of other pieces of paper from people whom they rarely see in parts of the hospital into which they rarely go. The 'analytical factory' aspect of our specialty is increasingly the province of our now highly trained technologists, for whom the area of work which has recently been termed 'non-exception reporting' lies firmly under the job description.
If clinical chemistry, as we understand it today, is to have the role we would wish it to have in the future, it must be seen that the profession is complementary and not supplementary to medicine. Accent on the difference between the two words must surely describe our destiny.
The programme in clinical chemistry followed at CRC Throughout the decade of the existence of the CRC, the Clinical Chemistry Division has used these philosophies to pursue work on fronts that have seemed relevant and suited to the limited sources available. Being a national centre, there is a duty to exploit in the best possible wayan ability to collaborate with national centres in other countries. We have considered that the purely professional front must not be ignored because medicine and medical research can thrive only so long as there are strong and happy professions upon which all work is based.
METHODOLOGY
It became apparent around 1970 that the Liebermann-Burchardt assay for cholesterol not only lacked precision and accuracy, but the corrosive reagents involved were not compatible with the valuable new instruments and machines becoming available. Dr. Richmond embarked upon the task of developing a completely new assay technique in the full knowledge that success may not be achieved for many years. The use of an enzyme seemed particularly appropriate but a bacterium had first to be found which produced a suitable enzyme. The micro-organism nocardia was a fortunate choice since the required enzyme was found to be present in the cell wall and was easily released without rupture of the cell itself. Again, Dr. Richmond was fortunate in that action of the enzyme on cholesterol produced easily measurable hydrogen peroxide. The scaling up of enzyme production to factory proportions was not easy and could not have been achieved without the very considerable help of Drs Lilly and Dunhill and their access to large fermenters at University College, London. The assay technique is now widely used (Richmond, 1973) . Licensing for commercial production of the enzyme was handled by the British National Research Development Corporation (NRDC), and financial return to the Corporation from this project now ranks among its top six. From the commercial exploitation of projects such as this the Division as a whole is a financial asset and not a liability to the British taxpayer.
Under the heading immunoassay, Dr. Byfield is working on a new approach to the immuno-type assays using the principle of molecular affinity rather than a biological immune reaction. A chemical dye or other suitable ligand is selected with a molecular configuration such that it will bind the LJ ./ gel Fig. 1 Mitchell substance that it is required to assay. This approach allows more chemical control than is possible with a biological immune system; if, for example, the specific site of biological activity in a molecule is chosen for binding, the resulting assay is likely to be specific for that activity. The use of this approach is exemplified in Fig. 1 ; an antibody will bind both thyroid globulin and a biologically active fragment, but a gel used for affinity assay binds only the active site both in the complete molecule and in an active fragment. The calibration curve for the assay is very similar to those obtained with radioimmunoassay systems. A lack of correlation for the two types of assay for thyroid binding globulin in serum indicates that two different entities are being measured, but the advantage of the affinity assay is that the entity is known, whereas it is unknown for the radioimmunoassay (Land and Byfield, 1978) .
APPLICATIONS OF NEWER TECHNOLOGY
Of the new techniques currently being exploited in clinical chemistry, one of those showing greatest promise is HPLe. Under an arrangement with Professor Knox in Edinburgh, Dr. Lim develops new chemical procedures on an HPLC 'breadboard', and then Professor Knox and his team design appropriate machinery for the practical application of the particular assay concerned. The first fruit of this collaboration has been an automatic instrument measuring creatinine in serum with a very high specificity, analysing 30 specimens per hour.
Gas chromatography-mass spectrometry (GC-MS) is so expensive as to be impractical at present for use in normal hospital laboratories. The Division's investment of£350 000 in GC-MS instrumentation is economically possible because it is operated for all the Divisions of the CRe. Among the many advantages of GC-MS are: its capacity to identify compounds with absolute certainty (except for certain epimers), discover the structures of new compounds and make quantitative measurements with high accuracy, even when the analyte is present in extremely low concentrations (Lawson, 1975) . It has been particularly valuable for studying steroid metabolism in the neonate. Until recently, available technology did not allow the analysis of the complex steroid patterns that are present in the blood and urine of both mother and infant during the neonatal period. With the help of mass spectrometry, Dr. Shackleton and his colleagues have, over the last 14 years, identified some 40 new steroids, some of which are quantitatively the major steroids in the newborn and almost certainly of considerable importance (Taylor et al., 1978; Shackleton et al., 1979) . Figure 2 shows capillary column gas chromatograms of the steroids in the urine of the normal adult, a normal infant, and an infant with an 18-oxidation defect in adlosterone biosynthesis. The peaks are identified by mass spectrometry, and the overall technique makes it possible to identify new steroids and produce accurate diagnoses of steroid metabolic dysfunction at a rate that could not be contemplated a few years ago.
With the firm belief that the ultimate in quality control must be the achievement of accuracy as well as precision, Dr. Pickup, in 1971, started work on definitive technology together with the National Bureau of Standards in Washington, DC. The analysis methods it is necessary to develop are complex and expensive but produce results as near to the true value as is currently possible. When the methods are applied to quality control sera, the results obtained serve as target values to ensure the accuracy of methods used for routine service (Rinsler and Mitchell, 1974) . The pioneering work on calcium measurement has now been completed with a trial of the reference method in 12 European laboratories conducted by Dr. Brown and financed from European Community funds.
Fig. 2 Gas chromatographic profile analysis of the urinary steroids (as methyloxime trimethylsilyl ethers) excreted by (a) a normal adult, (b) a normal 3-day-old infant, and (c) a 6-month-old infant with
Where possible, isotope dilution-mass spectrometry is the favoured technique; it was first adapted to the measurement of the elements, but before it could be applied to organic compounds many difficulties had to be overcome. Progress was made, however, and work on different organic analytes is now proceeding by mutual arrangement in several centres throughout the world. Dr. Lim has achieved success for uric acid (Lim et al., 1978a) , creatinine (Lim et al., 1978b) , the thyroid hormones, and bilirubin. For all, the major difficulties involved in the necessary initial purifications were overcome by utilising HPLC. In the past, clinical chemists have not necessarily had to define the analyte in precise terms for any particular analysis. For definitive technology this is the first consideration before the development of a technique can be contemplated. For example, in the case of bilirubin it has been necessary to discover the exact nature of the conjugated fraction. The results of this investigation have, on their own account, been most unexpected and interesting (Lim, 1979) .
Work on definitive analytical techniques for the steroids proved to be so expensive and difficult that it could only be organised on an international scale. It was possible, with finance from the European Community, to set up a group to carry out work in five European laboratories possessing mass spectrometers. The aim is to have definitively assayed reference sera available to all countries in the European Community, probably supplied from Holland. The first batches should be ready next year and will have been assayed for cortisol and oestradiol. The availability of this material should lead to a considerable improvement in the quality control of steroid assays generally.
When steroids are present as conjugates it is important to treat them as such for quality control accuracy purposes, and Dr. Setchell's column extraction techniques worked out with Professor Sjovall in Sweden are proving to be appropriate (Setchell et al., 1976 and .
INSTR UMENT AnON
With the collaboration of the CRC Division of Bioengineering, the Clinical Chemistry Division has been active in the design of instrumentation. After the development with Dr. Riley of the Vickers F. L. Mitchell M-300 and D-300 was completed in 1972, the GeMSAEC principle was studied carefully with a view to eliminating the major problem of loading, emptying, and washing tubes which are rapidly rotating in a centrifuge. Messrs Renshaw, Rideout, and Snook thought of rotating the light instead of the tubes, and in 1975 a new prototype analyser was produced and termed DACOS (discrete analyser with continuous optical scanning). The principle of operation is shown in Figure 3 . Light from a source at the top of the instrument passes a mechanism for rapidly changing the wavelength and is then reflected out to the reaction tube, traverses each tube twice with reflection, and returns to a detector at the bottom of the instrument. The optical mechanism rotates approximately once per second. Coulter Inc accepted a development licence from NRDC and, after major factory developments in Miami, the first commercial instruments should be available in 1980. The instrument will have an extremely high speed of continuous specimen throughput and will complete GeMSAEC-type kinetic measurements on each sample for a lengthy period if necessary.
In 1975, it was apparent that the design and production of instruments for clinical chemistry in the developed world was proceeding satisfactorily, and the ultimate in sophistication and efficiency appeared to be in sight. However, such instruments find satisfactory application only in countries with excellent electricity supplies, high levels of technology, good climates, and, above all, high econcmies. These criteria apply for perhaps only 20% of the world's population. When visiting countries in the developing world it becomes abundantly clear that lillie has been done to meet their unique requirements, and that systems developed in and for developed countries are almost universally inappropriate, often disastrously so.
The first WHO Consultations in Clinical Chemistry and Haematology were held in 1975 in Geneva and Bilthoven respectively (World Health Organization, 1975a, b) ; both concluded that the most urgent need in developing countries was for a robust colorimeter to measure haemoglobin and to provide basic analyses in clinical chemistry for glucose. urea, protein. bilirubin, etc. The development of such instruments proved to be more difficult and time-consuming than designing a high-speed computer-controlled analyser like DACOS. There are many possible designs for a cheap, robust instrument. and all had to be tried. A variety of instruments of varying complexity were produced, selling prices ranging from £50 to £250 (Hjelm et al .• 1979) . 
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There is little to be gained from the development of such instruments if the collection of blood and subsequent dilutions, reagent measurements, etc involve the use of expensive syringes and other measuring devices requiring a fair amount of skill in their use. After much thought and many trials the 'SwizzleStick' principle was proposed (Rideout, Renshaw and Snook, 1978) , in which a sample of blood or plasma is displaced by a wire probe from the capillary in which it was collected (Fig. 4) ; it is then mixed into premeasured reagent by 'swizzling' the stick. The capillary is centrifuged for plasma displacement. The precision available using this simple and cheap technique is better than that obtained with the use of the best rnicropipettes.
The WHO tested six complete prototype SwizzleSticks and colorimetric systems in different parts of the developing world. and in 1978 encouraging results were obtained together with a number of helpful comments and suggestions (Rideout, 1979) . From the experience thus gained, together with trials in The Gambia based on the MRC Tropical Medicine Research Station. a final instrument was constructed (Fig. 5) ; it is hoped that instruments based on the principles developed will soon be available. While developing the instruments described above, it has become apparent that the requirements of some of those who need clinical chemistry in the developed world-general practitioners, mobile collecting units for blood transfusion services, outpatient departments, clinics in remote areas, veterinary surgeons, etc-are very similar, and it is possible therefore that large, lucrative, unexpected markets could emerge for which products designed specifically for the developing world were not originally intended.
In supplying the needs of developing countries, equally important to the development of instruments and chemistry systems is the generation of suitable techniques for training the staff required for their operation. Dr. Woodward has for over two years been developing new teaching methods based on distance and discovery learning principles. She has successfully evaluated her prototype SIMs (selfinstruction materials) on a variety of types of person in The Gambia (Woodward, 1979) and will continue both in that country and elsewhere for the next three years, financed by the British Ministry of Overseas Development.
We believe that solid-phase, thin-layer, dry-tothe-touch chemistry will have a very considerable impact in the near future on analysis techniques for clinical chemistry, and it has been our privilege to work for several years with the extremely talented scientific team that Kodak has assembled for clinical chemistry work in Rochester, New York. Briefly, the principle is as follows: a photographic colour film can have up to 16 separate interacting layers of chemistry laid with very high precision on a supporting base. If clinical chemistry instead of photographic reagents are included in those layers, it is possible to carry out an analytical procedure with up to 16 stages. A small drop of serum is placed on the surface of a small piece of film, termed a chip. The make-up of the first layer on the film-the spreading layer-is such that the serum spreads evenly, and the constituents for assay pass into the next layer. The volume of serum is not critical, and one important advantage of the technique is the removal of the present need to measure the sample with a high degree of accuracy. The various stages of the analytical process proceed as the analyte permeates downwards, and finally a colour is developed in the last layer. Measurement is carried out by reflectance densitometry. Precision is high, as is accuracy when comparison is made with reference methods.
There seems to be no assay at present requiring clinical chemistry which, with a certain amount of ingenuity, cannot be transferred to this system.
F. L. Mitchell
Over the next five to 10 years this new approach must surely have a considerable impact on our specialty, but it is important to note that the preparation and measurement of all the chemicals has of necessity to be done in a Kodak-type factory, and the technology is such that development has to be done by specialists at present trained in the photographic industry. This is a most important example of the accelerating trend of our chemistry development to move to industry.
This type of measurement has many advantages for developed countries, but it is in countries and circumstances where there is little training in laboratory procedures that the application is most exciting.
CLINICAL RESEARCH
For a division of clinical chemistry situated in a purely clinical environment it is important not only to pursue independent research connected specifically with the specialty, but to provide complementary clinical support, not only when it is requested, but also to point out to the clinical divisions situations in which new laboratory developments may contribute to success. Dr Shackleton's steroid programme, already mentioned, is a good example of the way in which technology and clinical application can move ahead simultaneously with the clinical chemist working in full partnership with the clinician.
INTERNATIONAL RELATIONS
In its national role the CRC has a special responsibility for international collaboration, and the Medical Research Council is particularly anxious that medical research should be coordinated, at least in the European Community. In 1973 it was possible to persuade the Community Bureau of Reference of the Commission of the European Community to set up a Clinical Chemistry Advisory Committee with representatives from all European Community countries. Two years later, the haematologists formed a similar advisory committee and the two have now been merged. The forging of this European link has proved particularly valuable in arranging collaborative work on standardisation and reference materials, particularly when, as exemplified by the steroid definitive assay project mentioned earlier, the funds required are larger than those normally available from purely national resources.
From the meetings arranged under the aegis of the European Community came a scheme to form a European Committee of Clinical Chemistry Societies. This is currently engaged in the groundwork required to make proposals leading to the free interchange of qualifications in the specialty, at least between the countries of the European Community. In addition, it is hoped to arrange within a few years a universally acceptable examination on the lines of the British Mastership in Clinical Biochemistry, possibly organised with interchange of examiners between examining boards of different countries.
Through collaborative work on instrumentation with the International Federation of Clinical Chemistry, and working with several centres in the USA on definitive and reference technology, we realised the considerable value of the National Committee for Clinical Laboratory Standards (NCCLS) in the USA. This Committee is now generating two parametric (paper) standards per month, and, in the absence of other such standards throughout the world, these are being increasingly accepted for international use. It seemed appropriate that a similar sister organisation could operate in Europe and help in sharing the considerable workload with the NCCLS. Procedures towards the setting up of a European Committee for Clinical Laboratory Standards (ECCLS) started some 18 months ago, and the new Committee will be formed officially at the Third European Congress for Clinical Chemistry in Brighton in June 1979 (Note added July 1979-This Committee is now actively considering its future programme of work). In this Committee, governmental, professional, and industrial representatives will work together on an equal footing with the sole aim of improving clinical laboratory standards. The first moves to set up the ECCLS were made at the Association of Clinical Biochemists Advanced Course held at the CRC in 1974. When Professor Magnus Hjelm was seconded in 1977 from Odense University to organise the European Community Clinical Chemistry and Haematology Groups, he very capably took over the detailed organisation necessary to start the Committee, and any success that is achieved in the early years of its existence will be due largely to him.
PROFESSIONAL ACTIVITIES
We feel very strongly that so many efforts on so many fronts in our specialty could come to nought if the profession as we know it disintegrates. Each member of any profession has a duty to spend as much time as can be spared on matters concerning those organisations to which the profession owes so much for its cohesion and advancement-in our case, the Association of Clinical Biochemists (ACB) and the Royal College of Pathologists at home, and abroad the International Federation of Clinical Chemistry and the International Union of Pure and 297 Applied Chemistry. This work can be very demanding, but after rapid expansion we have by no means reached stability in our specialty, and during the next decade, more than at any other time, our ship needs good navigation and a good crew. It is essential to realise that time spent holding offices in organisations such as the ACB and the Royal College of Pathologists is just as valuable as time spent probing the frontiers of science.
In 1976 an ACB Working Party produced a report on 'The Organisation of Clinical Chemistry in the National Health Service'. This became known by some as the Mitchell Report and was modified somewhat before being accepted as an ACB policy document. A major feature of the orginal report was proposals to ensure a happy relationship between technical and scientific staff. If there have been successes in clinical chemistry at the CRC, they have been due in large part to our refusal in research work to acknowledge any magic difference between the two groups, and indeed many of the persons who have made important contributions to original research have been technicians or technical officers. In our clinical chemistry service work at Northwick Park Hospital we acknowledge the difference only in so far as it is necessary for the job description.
When I was asked to give this oration it took a little time to arrive at a title. Per ardua ad astrathrough toil to the stars-is, of course, the motto of the Royal Air Force. Let us all ensure that we do not over the next 10 years emulate Alcock and Brown, who, in a Vickers Vimy bomber, triumphantly flew the Atlantic for the first time but finished with the Vimy's nose in an Irish peat bog. If we do not carefully watch our philosophies, there is a distinct possibility that, for the reasons already stated, our profession and specialty could disintegrate. On the other hand, with good direction and leadership, clinical chemistry could continue its dramatic progress and take up an important position alongside medicine and surgery in the field of health care.
Special thanks are due to Drs Byfield and Shackleton, and Messrs Renshaw, Snook, and Taylor for permission to reproduce diagrams and a photograph.
